Role of intravascular ultrasound use in patients undergoing endovascular aortoiliac aneurysm repair Authors: Mohammed Alsagheer Alhewy, Mohamed Yahia Zakaria Mohamed, Mohamed Hamza Metwaly, Reda Othman Abbas, Ehab Abd Elmoneim Ghazala, Ahmed Atef Khamis, Abdallah Elsayed, Mohammed Ibrahim Hammoda Published: 2025 ABSTRACT BackgroundThis study aimed to assess the accuracy of aortic measurements obtained by intravascular ultrasound (IVUS) compared with intra-arterial contrast agents (IACA), and to evaluate the role of IVUS in endovascular repair of abdominal aortic aneurysms (EVAR), particularly in patients with chronic kidney disease (CKD).Patients and methodsThis prospective single-center study which was conducted in vascular surgery departments at Al-Azhar university hospitals from December 2017 to December 2022. It included eighty patients complaining of infrarenal abdominal aortic aneurysm (AAAs). According to treatment policy, patients were divided into two groups: Group A: treated by EVAR with an intra-arterial contrast agent. Group B: treated by EVAR with intravascular ultrasound;ResultsReceiver operating characteristic (ROC) curve analysis showed that access artery diameter (right or left iliac) measured by IVUS significantly predicted aneurysm sac size reduction after EVAR (AUC = 0.88, P = 0.003). At a cut-off > 14 mm, the access artery diameter yielded 100% sensitivity, 80% specificity, positive predictive value (PPV) of 83.3%, and negative predictive value (NPV) of 100%. A moderate agreement was observed between computed tomography angiography (CTA) and IVUS in assessing aortic dimensions. Larger access artery diameters (> 14 mm) were associated with less sac regression, possibly due to suboptimal distal sealing and increased risk of type Ib endoleaks.ConclusionIVUS is a valuable and accurate imaging tool compared to CTA for aortic measurements during EVAR, especially beneficial for patients with renal impairment by reducing contrast load and radiation exposure.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-025-03523-6. Introduction Endovascular repair of aortic aneurysms (EVAR) has been a common practice worldwide since the first report by Juan Parodi in 1991. Since this initial disclosure, several innovators have worked on broadening the indications of EVAR in treating patients with complex anatomy [1, 2] The initial utilization of the endovascular approach was directed towards managing elderly patients exhibiting significant comorbidities, rendering them unsuitable candidates for open surgical intervention. Nevertheless, the scope for employing this minimally invasive technique has markedly broadened since its inception. Presently, the predominant approach for managing anatomically appropriate infrarenal abdominal aortic aneurysms (AAAs) entails endovascular aneurysm repair (EVAR) as opposed to traditional open surgical repair [3, 4] Refinements in endovascular techniques have steadily improved perioperative survival rates among patients undergoing endovascular aneurysm repair (EVAR). EVAR procedures require intra-arterial contrast agents (IACA), which aid in verifying aortic aneurysm morphology and identifying the Ostia of renal and hypogastric arteries. However, IACA is not recommended for use in patients with renal dysfunctions or allergies to contrast agents. Since the 1990s, intravascular ultrasound (IVUS) has been used as an alternative to IACA [5–7] IVUS provides real-time imaging during aortic interventions, which is mandatory in evaluating and treating aortic pathologies, including aneurysms, dissection, and penetrating aortic ulcers (PAU). IVUS allows the anatomic definition of the target vessels and the relationship of branch vessels to the lesion, which are critical in confirming the diagnosis, endograft selection, and successful endovascular treatment [8–11]. IVUS is helpful for the assessment of access vessels, proximal and distal fixation sites, and accurate vessel sizing for endograft selection during endovascular abdominal aortic aneurysm repair (EVAR). Important anatomic structures, including the renal arteries for EVAR, can be identified, and located. IVUS can then provide imaging data that could only be obtained with angiography, thereby reducing the radiation dose and contrast load, which is particularly important in patients with compromised renal function [12]. This present study aims to assess the accuracy of aortic measurements with an intravascular ultrasound scan (IVUS) compared with an intra-arterial contrast agent and to determine the role of IVUS in the performance of endovascular repair of abdominal aortic aneurysm and its role in chronic kidney disease. Patients and methods This prospective, single-center study was conducted at Al-Azhar university hospitals vascular surgery departments from December 2017 to December 2022, including patients with infrarenal abdominal aortic aneurysm (AAA) eligible for endovascular aneurysm repair (EVAR). Inclusion criteria encompassed non-ruptured AAA (> 5.5 cm or > 0.5 cm growth in 6 months) and anatomic suitability confirmed by core lab CTA, including aortic neck length ≥ 15 mm, diameter < 28 mm, neck thrombus < 50% circumference, angulation < 60°, iliac access vessels ≥ 7 mm (external iliac), and aortic bifurcation ≥ 18 mm. Patients were assigned to Group A (IAC-EVAR), undergoing standard EVAR with iodinated contrast (Visipaque™ 320 mgI/mL), or Group B (IVUS-EVAR), which included patients with renal dysfunction (eGFR < 30 mL/min or Cr > 1.4 mg/dL) or documented contrast allergy. Prior to enrollment, all patients provided written informed consent after being counseled on the available imaging modalities. While alternative approaches such as low-contrast EVAR or CO₂ angiography were discussed when applicable, IVUS was offered as the preferred method in our center due to its availability, safety profile, and institutional expertise. Patients were not automatically assigned based on renal function; rather, they were informed of the risks and benefits and voluntarily consented to the IVUS-guided procedure. Exclusion criteria included anatomic contraindications such as aortic neck length < 15 mm or diameter ≥ 28 mm per device IFU, bilateral hypogastric artery coverage requirement, visceral artery occlusions (celiac/SMA), and non-anatomic exclusions such as essential accessory renal arteries. Patients exceeding anatomic EVAR limits (aortic neck diameter ≥ 28 mm, length < 15 mm) were excluded as they required open repair or custom devices, while those with thrombus > 50% circumference were excluded to ensure reliable IVUS measurements. Patient selection considerations Patients selected for EVAR with either IVUS or intra-arterial contrast agent fulfilled the relevant clinical and morphologic criteria. Documentation included a written medical history, including A history of the presenting symptoms, indications for the procedure, patient medical and surgical history, a list of current medications, allergic history, and vascular risk factors. Physical examination includes Palpation (pulsatile abdominal mass), auscultation (bruit over abdominal mass), a detailed vascular examination: Skin lesions, ankle-brachial indexes, pulse volume recordings, and general examination of sufficient depth to exclude significant concurrent illnesses. Investigations Laboratory (Blood picture including platelet count, Blood sugar level, Kidney functions, Liver functions, Coagulation profile), Radiological: Imaging studies which can be one of the following: CT. Angiography is a primary choice, MRA (magnetic resonant angiography), if the patient has contraindications to the above duplex ultrasonographic (US) examination. Although patients in the IVUS group underwent preoperative CTA with low-contrast protocols under nephroprotection, they were excluded from intraoperative contrast use due to the higher risk associated with intra-arterial contrast bolus during EVAR. PROCEDURE: Every case was studied individually, and according to the mentioned criteria, it was subjected to EVAR using either an intra-arterial contrast agent or intravascular ultrasound. The procedure was done in the operation room under a complete aseptic technique with a radiologic angiography suite. At the end of each procedure, the details of the technique were documented individually regarding Anesthesia: local, regional, or general, arterial access (open femoral artery exposure (percutaneous access was not used due to limited availability of closure devices at our center during the study period)), use of intra-arterial contrast agent or intravascular ultrasound, duration of the procedure, equipment used: Sheath (Fr) size, guidewire type, guiding catheters used, type of endograft delivered, size of contralateral limb placed, proximal and distal fixation points as well as all overlap points should then be angioplastied (ballooned), detection of the presence of endoleaks ( angiogram or IVUS) percutaneous access was not used due to limited availability of closure devices at our center during the study period. Medications Peri-procedural: Cessation of chronic anticoagulation is necessary before EVAR, but antiplatelet agents can be continued unless epidural anesthesia is planned. Patients with marginal renal function may be prehydrated, and sodium bicarbonate, N-acetylcysteine, and isosmolar contrast agents may be considered. Perioperative antibiotics and subcutaneous heparin are administered. Intra-procedural: Patients will receive a bolus of 5,000 IU of heparin (70 to 100 U/kg) after insertion of the sheath in the common femoral artery. Post-procedural: Clopidogrel 75 mg/ day for 12 weeks, Aspirin 100 mg/day, and statins (Atorvastatin) 20 mg/day for 90 days. Study endpoint: Primary endpoints were defined per Society for Vascular Surgery (SVS) reporting standards: technical success (successful endograft deployment without Type I or III endoleak on completion imaging), procedural success (technical success plus absence of major adverse cardiac/cerebrovascular events [MACCE] within 30 days), and clinical success, defined as aneurysm sac regression ≥ 5 mm at 1-year follow-up imaging, in the absence of rupture, conversion to open repair, or aneurysm-related mortality. Patient follow-up Patients were evaluated through follow-up clinic visits at 1-, 3-, 6-, and 12-months post-procedure, regarding the following points: Sustained clinical improvement (absence of abdominal, urinary symptoms, and pulsating mass), monitoring of kidney function, the control of risk factors (e.g., smoking, D.M, hypertension, hyperlipidemia), and color duplex ultrasound and CTA scan. Postoperative surveillance allows the detection of endoleaks, aneurysm sac expansion, stent fracture, limb kinking, and material fatigue. Statistical analysis All analyses were performed using SPSS version 28 (IBM), with continuous variables reported as mean ± standard deviation after normality confirmation via Shapiro-Wilk testing, employing Student’s t-test for normally distributed data and Mann-Whitney U tests for non-normal distributions, while categorical variables were analyzed using Fisher’s exact test; method agreement between IVUS and CTA measurements was assessed through Bland-Altman plots, and a pre-study power analysis determined the sample size provided 80% power (α = 0.05) to detect a clinically significant 15% difference in aneurysm sac regression between groups. A pre-study power analysis determined that 40 patients per group were needed to detect a 15% difference in sac regression with 80% power and α = 0.05. Approximately 200 EVARs were performed during the study period, and 80 patients (40%) met all eligibility criteria and were enrolled. Results This prospective study was conducted at Al-Azhar university hospitals from December 2017 to December 2022 on eighty patients complaining of infrarenal abdominal aortic aneurysm, divided into two groups: Group A: included forty patients with infrarenal abdominal aortic aneurysm whom EVAR conducted with an intra-arterial contrast agent, and Group B: included forty patients with infrarenal abdominal aortic aneurysm in whom EVAR were conducted with intravascular ultrasound the two studied groups were comparable in age and sex distribution. The age of patients of group A (69.4 ± 8.28. range: 57–87), while the age of patients of group B (64.2 ± 6.51. range: 55–74). Patients of group A were thirty-six males (90%) and four females (10%), also patients of group B were thirty-two males (80%) and eight females (20%). There was no statistically significant difference between both groups as regards the prevalence of DM, HTN, cardiac affection, and smoking, as shown in [ Fig. 1] There was no statistically significant difference between both groups in terms of the complaint, as shown in [ Fig. 2] By comparing both groups regarding aortic measurements, access artery diameter (right or left iliac) was significantly higher in group B (treated by EVAR with IVUS) as compared to group A (treated by EVAR with intra-arterial contrast agent) (P value = 0.004). On the other hand, there was no statistically significant difference between both groups regarding AAA diameter, aortic neck length, aortic neck angulation, aortic bifurcation diameter, and aortic neck diameter, as shown in [Table 1] There was a significant difference in serum creatinine levels between the studied groups being higher in patients treated by EVAR with IVUS as compared to those treated by EVAR with intra-arterial contrast agent (P < 0.001). as shown in [figure 3] We performed all procedures on our patients under general anesthesia and underwent arterial cutdown for arterial access. The mean procedure duration was significantly longer in the IVUS group (3.1 ± 0.28 h) compared to the contrast group (2.5 ± 0.41 h, p = 0.003). Regarding technical success, it was achieved in all patients in both groups. as shown in [Table 2] As shown in [Table 3], there was no statistically significant difference between the studied groups in terms of Periprocedural complications (only four patients treated by EVAR with intra-arterial contrast agent experienced groin hematoma), 30-day mortality was 0% in both groups, Sustained clinical improvement and CT angiography results (all cases in both groups were clinically improved with normal CT angiography except four cases treated by EVAR with intra-arterial contrast agent suffered from late-type 1b endo-leak after 12 months). Fig. 1Vascular risk factors of the studied groups Vascular risk factors of the studied groups Fig. 2Complaints of the studied groups Complaints of the studied groups Table 1Aortic measurements of the studied groupsGroup A(n = 40)Group B(n = 40)P valueDiameter (cm)7.5 ± 1.497.1 ± 1.260.615.5–9.55.5–9Aortic neck length (mm)23.8 ± 6.3727.3 ± 5.10.19215–3420–35Aortic neck angulation (degree)33.7 ± 12.2533 ± 12.010.89915–5820–50Aortic bifurcation diameter (mm)27.3 ± 4.8829.2 ± 8.790.55818–3219–42Aortic neck diameter (mm)24.8 ± 4.2627.8 ± 3.080.08819–3224–32Access artery diameter (iliac) (mm)11.7 ± 2.3115.2 ± 2.49 0.004* 10–1712–19Data are presented as mean ± SD and range, *: Statistically significant as P value < 0.05 Table 1Aortic measurements of the studied groupsGroup A(n = 40)Group B(n = 40)P valueDiameter (cm)7.5 ± 1.497.1 ± 1.260.615.5–9.55.5–9Aortic neck length (mm)23.8 ± 6.3727.3 ± 5.10.19215–3420–35Aortic neck angulation (degree)33.7 ± 12.2533 ± 12.010.89915–5820–50Aortic bifurcation diameter (mm)27.3 ± 4.8829.2 ± 8.790.55818–3219–42Aortic neck diameter (mm)24.8 ± 4.2627.8 ± 3.080.08819–3224–32Access artery diameter (iliac) (mm)11.7 ± 2.3115.2 ± 2.49 0.004* 10–1712–19Data are presented as mean ± SD and range, *: Statistically significant as P value < 0.05 Aortic measurements of the studied groups Data are presented as mean ± SD and range, *: Statistically significant as P value < 0.05 Fig. 3Serum creatinine level of the studied groups Serum creatinine level of the studied groups Table 2Procedural data of the studied groupsGroup A(n = 40)Group B(n = 40)P valueDuration of procedure (hr)Mean ± SD2.5 ± 0.413.1 ± 0.280.003*Range2–32.5–3.5Technical successYes40 (100%)40 (100%)---No0 (0%)0 (0%)Clinical successDecrease in size8(20%)20 (50%)0.364Relief of symptoms24 (60%)16 (40%)Relief of symptoms and control of leak8 (20%)4 (10%)Data are presented as frequency (%), *: Statistically significant as P < 0.05 Table 2Procedural data of the studied groupsGroup A(n = 40)Group B(n = 40)P valueDuration of procedure (hr)Mean ± SD2.5 ± 0.413.1 ± 0.280.003*Range2–32.5–3.5Technical successYes40 (100%)40 (100%)---No0 (0%)0 (0%)Clinical successDecrease in size8(20%)20 (50%)0.364Relief of symptoms24 (60%)16 (40%)Relief of symptoms and control of leak8 (20%)4 (10%)Data are presented as frequency (%), *: Statistically significant as P < 0.05 Procedural data of the studied groups Data are presented as frequency (%), *: Statistically significant as P < 0.05 Table 3Outcome of EVAR techniques of infrarenal abdominal aortic aneurysm in the studied patientsGroup A(n = 40)Group B(n = 40)P valuePeriprocedural complicationsNo complications36(90%)40(100%)> 0.999Groin hematoma4 (10%)0 (0%)30 days mortalityNo40 (100%)32 (80%)> 0.999Yes0 (0%)8 (20%)Sustained clinical improvementImproved36(90%)40 (100%)> 0.999Late type 1b endo-leak after 12 months4 (10%)0 (0%)CT AngioNormal36(90%)40 (100%)> 0.999Endo-leak with aneurysmal common iliac after 12 months4 (10%)0 (0%)Data are presented as frequency (%) Table 3Outcome of EVAR techniques of infrarenal abdominal aortic aneurysm in the studied patientsGroup A(n = 40)Group B(n = 40)P valuePeriprocedural complicationsNo complications36(90%)40(100%)> 0.999Groin hematoma4 (10%)0 (0%)30 days mortalityNo40 (100%)32 (80%)> 0.999Yes0 (0%)8 (20%)Sustained clinical improvementImproved36(90%)40 (100%)> 0.999Late type 1b endo-leak after 12 months4 (10%)0 (0%)CT AngioNormal36(90%)40 (100%)> 0.999Endo-leak with aneurysmal common iliac after 12 months4 (10%)0 (0%)Data are presented as frequency (%) Outcome of EVAR techniques of infrarenal abdominal aortic aneurysm in the studied patients Data are presented as frequency (%) Based on ROC curve analysis, access artery diameter (right or left iliac) by IVUS can significantly predict the effect of EVAR in decreasing aneurysmal size (AUC = 0.88, P = 0.003). At cut-off > 14 mm, access artery diameter gives a sensitivity of 100%, specificity of 80%, PPV of 83.3%, and NPV of 100%, as shown in [Table 4], and [ Fig. 4] Bland-Altman analysis shows that there was a reasonable degree of agreement between CT and IVUS in the evaluation of different aortic measurements with a mean bias of [-0.07 ± 0.61, LLOA (95%CI): -1.26 (-2.03 to -0.491), ULOA (95%CI): 1.12 (0.351 to 1.89) for aortic diameter], [-0.9 ± 2.28, LLOA (95%CI): -5.37 (-8.265 to -2.483), ULOA (95%CI): 3.57 (0.683 to 6.465) for Aortic neck length], [1.1 ± 6.52, LLOA (95%CI): -11.68 (-19.945 to -3.423), ULOA (95%CI): 13.88 (5.623 to 22.145) for Aortic bifurcation diameter], [0.9 ± 3.07, LLOA (95%CI): -5.12 (-9.01 to -1.23), ULOA (95%CI): 6.92 (3.03 to 10.81) for Aortic neck diameter], [0.9 ± 3.25, LLOA (95%CI): -5.47 (-9.577 to -1.352), ULOA (95%CI): 7.26 (3.152 to 11.377) for access artery diameter] as shown in [ Fig. 5] and [ Fig. 6]. Lastly, there was no statistically significant difference between CT and IVUS regarding aortic measurements in patients with chronic kidney disease as shown in [Table 5]. Although not statistically significant, groin hematoma occurred in 10% of patients in the contrast group and 0% in the IVUS group. Table 4Diagnostic performance of aortic measurements with IVUS in predicting the decrease in aneurysmal sizeCut offSensitivitySpecificityPPVNPVAUCP valueDiameter (cm)≤ 5.54010010062.50.620.562Aortic neck length (mm)≤ 236010010071.40.60.683Aortic neck angulation (degree)> 221006071.41000.760.141Aortic bifurcation diameter (mm)≤ 194010010062.50.520.931Aortic neck diameter (mm)≤ 244010010062.50.580.692Access artery diameter (iliac) (mm)> 141008083.31000.880.003*AUC: Area under the curve, PPV: Positive predictive value, NPV: Negative predictive value Table 4Diagnostic performance of aortic measurements with IVUS in predicting the decrease in aneurysmal sizeCut offSensitivitySpecificityPPVNPVAUCP valueDiameter (cm)≤ 5.54010010062.50.620.562Aortic neck length (mm)≤ 236010010071.40.60.683Aortic neck angulation (degree)> 221006071.41000.760.141Aortic bifurcation diameter (mm)≤ 194010010062.50.520.931Aortic neck diameter (mm)≤ 244010010062.50.580.692Access artery diameter (iliac) (mm)> 141008083.31000.880.003*AUC: Area under the curve, PPV: Positive predictive value, NPV: Negative predictive value Diagnostic performance of aortic measurements with IVUS in predicting the decrease in aneurysmal size AUC: Area under the curve, PPV: Positive predictive value, NPV: Negative predictive value Fig. 4ROC curve analysis of access artery diameter by IVUS in predicting the decrease in aneurysmal size ROC curve analysis of access artery diameter by IVUS in predicting the decrease in aneurysmal size Fig. 5Bland-Altman plot for the agreement between CT and IVUS in terms of aortic diameter Bland-Altman plot for the agreement between CT and IVUS in terms of aortic diameter Fig. 6Bland-Altman plot for the agreement between CT and IVUS in terms of aortic neck length Bland-Altman plot for the agreement between CT and IVUS in terms of aortic neck length Table 5Comparison between CT and IVUS regarding aortic measurements of the same group of patientsCTIVUSP valueDiameter (cm)7.1 ± 1.167.1 ± 1.260.8996–9.55.5–9Aortic neck length (mm)26.4 ± 4.1427.3 ± 5.10.6719–3520–35Aortic bifurcation diameter (mm)30.3 ± 829.2 ± 8.790.77321–4019–42Aortic neck diameter (mm)28.7 ± 3.1627.8 ± 3.080.52824–3224–32Access artery diameter (iliac) (mm)16.1 ± 2.0815.2 ± 2.490.39112–1912–19Data are presented as mean ± SD and range Table 5Comparison between CT and IVUS regarding aortic measurements of the same group of patientsCTIVUSP valueDiameter (cm)7.1 ± 1.167.1 ± 1.260.8996–9.55.5–9Aortic neck length (mm)26.4 ± 4.1427.3 ± 5.10.6719–3520–35Aortic bifurcation diameter (mm)30.3 ± 829.2 ± 8.790.77321–4019–42Aortic neck diameter (mm)28.7 ± 3.1627.8 ± 3.080.52824–3224–32Access artery diameter (iliac) (mm)16.1 ± 2.0815.2 ± 2.490.39112–1912–19Data are presented as mean ± SD and range Comparison between CT and IVUS regarding aortic measurements of the same group of patients Data are presented as mean ± SD and range Discussion This study evaluated the role of intravascular ultrasound (IVUS) in endovascular aneurysm repair (EVAR), particularly in patients with chronic kidney disease (CKD), by comparing it to standard EVAR guided by intra-arterial contrast agents (IACA). Our findings demonstrate that IVUS can offer comparable diagnostic accuracy and procedural success while providing specific advantages in renal-compromised patients. Tsujimura et al. [13] found that in patients treated with IVUS use, implanted stents in these patients were longer and smaller in diameter. One of the most significant findings in our study was the ability of IVUS-derived access artery diameter to predict a decrease in aneurysmal size post-EVAR, with a high degree of accuracy (AUC = 0.88). This aligns with findings from Vogt et al. [14] who reported higher predictive value and sensitivity for IVUS over arteriography in iliac artery assessments. Similarly, Fernández et al. [15] demonstrated that IVUS altered the stent-graft size selection in over half of their cases, underscoring its utility in procedural planning. These results suggest that IVUS not only matches conventional imaging in measurement accuracy but also contributes meaningfully to intraoperative decision-making. Jánosi et al. [16] found that the mean diameters in the abdominal aorta were slightly higher, and the diameters of the infrarenal aortic aneurysm were significantly higher on CT compared to IVUS. Another important observation was the higher baseline serum creatinine in the IVUS group. This reflects real-world clinical practice, where IVUS is often used in patients with impaired renal function to avoid contrast-induced nephropathy. Hoshina et al. [5] similarly reported more frequent renal dysfunction in patients selected for IVUS-guided procedures. In our cohort, despite this higher risk profile, IVUS-guided EVAR resulted in no periprocedural renal complications, supporting the safety of IVUS in this subgroup. It is important to note that although patients in the IVUS group underwent preoperative CTA, this was performed using minimized contrast volume under renal protection protocols. Intra-arterial contrast during EVAR poses a different physiological risk due to higher contrast doses and direct arterial delivery, which could exacerbate renal injury in already impaired patients. Burlacu et al. [17] reinforced this point, concluding that IVUS-guided interventions are both safe and effective in patients with CKD. We found no statistically significant difference in clinical outcomes, periprocedural complications, or one-year imaging follow-up results between the two groups. This agrees with the findings of Von Segesser et al. [18]who reported similar surgical outcomes between IVUS and angiography-guided EVAR. However, they observed fewer early endoleaks in the IVUS group, a trend also noted in our study [endoleaks for IVUS (6.1%) angiography (25.8%: p5 0.05).] Intraoperative detection of endoleaks using IVUS is another important aspect of its clinical utility. The agreement between CT and IVUS for aortic measurements was strong in our analysis, as confirmed by Bland-Altman plots. This is consistent with prior validation studies. For example, Blasco et al. [19] and Jánosi et al. [16] reported high correlation coefficients between IVUS and CT measurements, with minimal systematic bias. Our data support the conclusion that IVUS is a reliable tool for aortic diameter, neck length, and bifurcation assessment. Additionally, the enhanced sensitivity of IVUS for endoleak detection has been documented by Bredahl et al. [20]who found improved diagnostic accuracy when IVUS replaced duplex ultrasound. the sensitivity of endoleak detection improved from 45.6% (95% CI 33.5–58.1%) to 85.3% (95% CI 74.6–92.7%) (p < 0.001). While our study did not focus primarily on endoleak detection, the absence of missed endoleaks in the IVUS group supports its diagnostic reliability. Tsujimura et al. [13] found that the 12-month restenosis risk was not significantly different between patients with and without IVUS use (10.2% [6.9 to 14.9%] versus 10.3% [5.4 to 18.6%], P = 0.99). In this study, we cleared that based on ROC curve analysis, access artery diameter (right or left iliac) by IVUS can significantly predict the effect of EVAR in decreasing aneurysmal size (AUC = 0.88, P = 0.003). At cut-off > 14 mm, access artery diameter gives a sensitivity of 100%, specificity of 80%, PPV of 83.3%, and NPV of 100% Vogt et al. [14] found that IVUS had superior predictive values and diagnostic accuracy compared to arteriography for aneurysm size reduction prediction. Logistic regression analysis supported IVUS as an independent predictor for favorable aneurysmal remodeling. In the present study, we found that there was a reasonable degree of agreement between CT and IVUS in the evaluation of different aortic measurements with a mean bias of [-0.07 ± 0.61 mm for aortic diameter], [-0.9 ± 2.28 mm for aortic neck length], [1.1 ± 6.52 mm for aortic bifurcation diameter], [0.9 ± 3.07 mm for aortic neck diameter], and [0.9 ± 3.25 mm for access artery diameter]. Blasco et al. [19] found that the mean of the diameters was: CT min, 27.4 (9.2) mm; CT mean, 28.3 (9.8) mm; IVUS, 27.9 (9.7) mm. The correlation between methods was good (r = 0.98; P < 0.001). The mean difference (MD) of absolute values was 1.33 (1.3) mm. Systematic error (SE) between CT min and IVUS was 0.59 (1.78) mm (P = 0.077). Beeman et al. [21] also believe that vascular ultrasound is more accurate than CTA in identifying patency and other problems, such as kinking and stenosis. Pearce and Jordan [8] previously noted that IVUS can streamline anatomical evaluation without requiring contrast or extensive fluoroscopy, thereby reducing radiation exposure a critical consideration in endovascular procedures. It is worth noting that our study has some limitations. First, it is a Single-Center Study. Second, the follow-up period was short. Thus, longer follow-up periods would be needed to evaluate the Role of Intravascular Ultrasound Use in Patients Undergoing Endovascular Aortoiliac Aneurysm Repair. Third, the study sample size was small, which may have limited the statistical power of the analysis. Fourth, the study focused on infrarenal abdominal aortic aneurysms, the generalizability of the findings to other aortic conditions or anatomical locations may require further investigation. Therefore, conducting further research with rigorous study designs will contribute to a more comprehensive understanding of the Role of Intravascular Ultrasound Use in Patients Undergoing Endovascular Aortoiliac Aneurysm Repair. In summary, our findings suggest that IVUS is a valuable alternative imaging modality for EVAR, particularly in patients at risk for contrast-induced nephropathy. It provides accurate measurements, supports safe and effective repair, and aligns well with existing literature. Future research should explore its role in broader patient populations and more complex aortic pathologies. Conclusion In conclusion, intravascular ultrasound (IVUS) emerges as a valuable and reliable tool for accurately assessing aortic measures in the context of abdominal aortic aneurysm repair. Our study suggests that IVUS compares favorably to CT angiography, highlighting its potential to enhance the precision of aortic measurements during endovascular interventions when compared to CT angiography in repairing abdominal aortic aneurysms. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1